Delay For Sanofi’s OTC Cialis Study In US Could Be Sign of Hurdles Holding Back Other Switches
Potential hurdles FDA put in front of Sanofi’s planned tadalafil switch could be sign for agency’s expectations for moving other Rx ingredients to OTC. Sanofi announced its planned actual use trial to support OTC tadalafil use was “placed on clinical hold due to matters surrounding the protocol design.”
You may also be interested in...
Sanofi Hopes UK Cialis Launch Will Illustrate US Switch Potential
Sanofi's upcoming launch of OTC Cialis in the UK “is quite important for getting a sense of what the over-the-counter opportunity could be and the appetite [in the US],” according to company CEO Paul Hudson.
Sanofi Sees Tough Economic Environment Start To Temper Demand
Sanofi Consumer Healthcare is starting to feel the effects of the tough economic environment, with signs of "growth moderation" in recent months. While the firm's global Q3 sales advanced by almost 2%, turnover in the US was hit by a "broad market slowdown."
Euro Q3 Consumer Health Earnings Preview: Helm Changes, Investor Questions, Results Debut
Major Europe-based consumer health players Reckitt, Bayer, Sanofi and Haleon feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2022 results over the coming weeks.